Fixed-Duration Therapy Works as Effectively as Continuous Treatment for Chronic Lymphocytic Leukemia

Fixed-Duration or Continuous Therapy in CLL: Trial Says Take Your Pick

(MedPage Today) -- ORLANDO -- A year of combination therapy for previously untreated chronic lymphocytic leukemia (CLL) patients led to similar outcomes compared with indefinite BTK inhibition with ibrutinib (Imbruvica) alone, an interim analysis...

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

Fixed-Duration Venetoclax Regimens Yield Noninferior CLL PFS to Ibrutinib

Fixed-duration venetoclax combined obinutuzumab or ibrutinib produced noninferior PFS compared with continuous ibrutinib monotherapy.

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.

Fixed-Duration Venetoclax Combos Noninferior to Ibrutinib Monotherapy in CLL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.